GLP1 receptor agonists (GLP1RA) such as semaglutide, liraglutide, and the combined GIP/GLP1RA tirzepatide have revolutionized pharmacotherapy for obesity; initially developed for diabetes treatment, they showed better glycaemic control as well as lower body weight in treated patients and have been approved for obesity management. Here, GIP is linked to obesity due to melanocortin 4 receptor deficiency.